Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent
- 1 July 1998
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 12 (10) , 1129-1138
- https://doi.org/10.1097/00002030-199810000-00004
Abstract
Thiocarboxanilide UC-781 is a highly potent and selective nonnucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1, which also has virucidal properties. Recent studies have shown that UC-781 would seem an ideal candidate for application as a vaginal virucide. To investigate the antiviral potency and stability of UC-781 in a lipophilic gel formulation. UC-781 was formulated in replens gel at different concentrations and administered intravaginally to rabbits at 5% in replens gel for 10 days. UC-781 was also exposed to temperatures of 4, 37 and 50°C, and to low pH (6.0, 4.3, 2.0 and 1.2). A number of microorganisms were exposed in culture to serial dilutions of UC-781. The drug was stable under low pH conditions and did not lose its antiviral potency upon 4 h exposure to pH 3.5 (the estimated vaginal pH). UC-781 can be easily formulated into a lipophilic gel (replens; up to 5%) and proved fully stable at 50°C for 30 days. There was no effect on the growth of microorganisms (i.e., Candida and Lactobacillus strains) that are present in the vaginal flora. Neither systemic side-effects, nor local inflammation or damage of the vaginal mucosa or epithelium were observed in rabbits to which 5% UC-781 in replens gel had been administered. UC-781, formulated as 0.5, 0.2 and 0.05% replens gel, and UC-38, α-APA and zidovudine, formulated as 0.5 or 0.2% replens gel, were effective in protecting CEM cells in the very beginning against productive HIV-1 replication. This points to an efficient diffusion of the drugs from the lipophilic gel to the hydrophilic culture medium. However, subsequent subcultivations at a dilution rate of 1 : 10 every 3–4 days resulted in a rapid breakthrough of virus with all drugs except UC-781 in its 0.5 and 0.2% gel formulation. These cultures were fully protected against HIV-1 and remained completely cleared from virus for at least 10 subcultivations. The virus that emerged under 0.05% UC-781 remained highly sensitive to the NNRTI, including UC-781, in cell culture, suggesting a lack of resistance development under our experimental conditions.Keywords
This publication has 18 references indexed in Scilit:
- The Thiocarboxanilide Nonnucleoside UC781 Is a Tight-Binding Inhibitor of HIV-1 Reverse TranscriptaseBiochemistry, 1997
- Development of Vaginal Microbicides for the Prevention of Heterosexual Transmission of HIVJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996
- Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strainsAntiviral Research, 1995
- Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives).Proceedings of the National Academy of Sciences, 1995
- Antiviral therapy for human immunodeficiency virus infectionsClinical Microbiology Reviews, 1995
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs)Expert Opinion on Investigational Drugs, 1994
- Challenges for the development of female-controlled vaginal microbicidesAIDS, 1994
- Barrier contraceptive use and HIV infection among high-risk women in CameroonAIDS, 1993
- Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutesJAMA, 1992
- Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction.Proceedings of the National Academy of Sciences, 1991